Koffi K G, Nanho D C, N'dathz E, Kouehion P, Dissieka R, Attia A, Mozard K, Tolo A, Boidy K, Meité N, Ayemou R, Sekongo M, Tea N, Sanogo I
Haematology National Teaching Hospital of Abidjan, 21 BP 632, Abidjan 21, Cote d'Ivoire.
Adv Hematol. 2010;2010. doi: 10.1155/2010/268921. Epub 2010 Aug 25.
Imatinib mesylate, showed encouraging activity in chronic myelogenous leukemia. However, there are few data regarding his efficacy and response monitoring in Sub-Saharan African patients. Our objective was to assess response to imatinib mesylate (Glivec) in Côte d'Ivoire patients with newly diagnosed Chronic Myeloid Leukemia (CML). From May 2005 to September 2009, we treated 42 patients (40 years; range 16-69) with Philadelphia chromosome (Ph+) positive in chronic phase CML with oral imatinib mesylate at daily doses of 400 mg. Overall survival (OS) and frequency of complete or major cytogenetic remission (CCR/MCR) were evaluated. At a median follow up of 32 (range 7.6-113) months, the CHR rate in our study group was 76%. A major CR was found in 19 patients (45%) with 17% and 29% complete and partial CR respectively. There were no significant differences in the incidence of major cytogenetic response by known prognostics factors. Median time to CHR was 8 months (range 0.4-25), and 16 months (range: 0.1-36) for CR. Projected 5-year OS rate was 72% (95%CI 42-88). We conclude that imatinib therapy sub-Saharan African CML patients is very promising and has favorably changed the prognosis for black African patients with CML.
甲磺酸伊马替尼在慢性粒细胞白血病中显示出令人鼓舞的活性。然而，关于撒哈拉以南非洲患者中其疗效和反应监测的数据很少。我们的目的是评估科特迪瓦新诊断的慢性髓性白血病（CML）患者对甲磺酸伊马替尼（格列卫）的反应。从2005年5月至2009年9月，我们用每日剂量400毫克的口服甲磺酸伊马替尼治疗了42例慢性期CML且费城染色体（Ph +）阳性的患者（年龄40岁；范围16 - 69岁）。评估了总生存期（OS）以及完全或主要细胞遗传学缓解（CCR/MCR）的频率。在中位随访32个月（范围7.6 - 113个月）时，我们研究组的细胞遗传学缓解率（CHR）为76%。19例患者（45%）出现主要完全缓解，其中完全缓解和部分缓解分别为17%和29%。已知的预后因素在主要细胞遗传学反应发生率方面无显著差异。达到CHR的中位时间为8个月（范围0.4 - 25个月），达到完全缓解的中位时间为16个月（范围0.1 - 36个月）。预计5年总生存率为72%（95%置信区间42 - 88）。我们得出结论，甲磺酸伊马替尼治疗撒哈拉以南非洲CML患者前景非常乐观，并且有利地改变了非洲黑人CML患者的预后。
